TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is planning preclinical studies that pair its PH1 spliceosome-modulating payload with Whitehawk Therapeutics' topoisomerase I inhibitor (TOP1i) ADC platform, CEO Abizer Gaslightwala said in a Virtual Investor "What This Means" interview.

TAMPA, FL – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is pairing its proprietary PH1 spliceosome-modulating payload with WhiteHawk Therapeutics' TOP1 inhibitor antibody drug conjugate (ADC) platform to test a dual-payload approach in oncology. President and CEO Abizer Gaslightwala laid out the rationale in a new CEO Corner segment released today. The release does not disclose financial terms.

Tampa – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported a second-quarter 2026 net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending tripled to $2.1 million ahead of a planned Phase 1 start for its lead antibody drug conjugate (ADC), AKTX-101, in mid-2027.

TAMPA – – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported that its TROP2-targeted ADC AKTX-101 slowed tumor growth in urothelial cancer models with limited response to Padcev or acquired resistance to Trodelvy. The company is targeting a Phase 1 start in mid-2027.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is targeting a First-In-Human trial of its lead antibody drug conjugate (ADC), AKTX-101, by mid-2027, after starting IND-enabling studies. The company laid out its investment case in the Virtual Investor "Why Now" on-demand conference.

CEO Abizer Gaslightwala argued that now is a pivotal time for Akari. He cited a fast-changing ADC landscape and rising industry demand for differentiated payload technologies.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has filed international patent application PCT/US2026/45955, adding claims on how its PH1 payload modulates alternative splicing across multiple cancer-driving genes.

Tampa, FL and London – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has appointed Vatnak Vat-Ho as Chief Business Officer, adding an executive who has held senior roles in oncology transactions totaling more than $25 billion in aggregate value.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) plans to begin Phase 1 clinical development of its lead antibody drug conjugate, AKTX-101, in mid-2027, with the compound now moving through IND-enabling toxicology and safety studies and large-scale GMP manufacturing.

CEO Abizer Gaslightwala laid out the strategy in a new CEO Corner segment. He argues that payload differentiation will matter more as ADCs move into front-line therapy and patients develop resistance to current payload classes, leaving few follow-on options.

Global – October 27, 2026 -- Declaration-based trade data cannot identify the vessels customs agencies most need to stop, according to a Windward analysis that points to a UK cocaine seizure worth roughly $100 million at London Gateway as proof.

Singapore – October 27, 2026 -- Teekay hosted two interns for 12 weeks through a Maritime and Port Authority of Singapore (MPA) program, and one of them built a machine learning workflow to forecast vessel earnings from voyage, market, bunker, port and utilization data.